XBiotech is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is John Simard. XBiotech Inc is engaged in discovering and developing True Human antibody technology monoclonal antibodies for treating a variety of diseases.



Previous Intraday Performance:

The XBIT shares had a previous change of -1.96% which opened at 7.21 and closed at 6.99. It moved to an intraday high of 7.36 and a low of 6.90.

SeekingAlpha:  Daily Insider Ratings Round Up 6/6/19

Historical Performance:

Over the last five trading days, XBIT shares returned -10.38% and in the past 30 trading days it returned -24.10%. Over three months, it changed -30.45%. In one year it has changed 63.70% and within that year its 52 week high was 11.74 and its 52 week low was 2.13. XBIT stock is 228.17% above its 52 week low.

Our calculations result in a 200 day moving average of 6.48 and a 50 day moving average of 8.88. Right now, XBIT stock is trading 7.94% above its 200 day moving average.

SeekingAlpha:  Daily Insider Ratings Round Up 6/6/19

Liquidity:

The company has a market cap of $286.3m with 41.0m shares outstanding and a float of 27.0m shares. Trading volume was 121,830 shares and has experienced an average volume of 170,255 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for XBiotech was -0.58 which ended on 31st of December 2018.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-09-2019: -0.16
4thQtr 2018Reported 03-13-2019: -0.17
3rdQtr 2018Reported 10-31-2018: -0.14
2ndQtr 2018Reported 08-09-2018: -0.16
1stQtr 2018Reported 05-08-2018: -0.11

The long-term trend of the EPS is an important number as it indicates the present value of XBiotech.

Indicators Also to Watch:

Based on the latest filings, there is 10.50% of institutional ownership.



The beta was calculated to be 0.43.

SeekingAlpha:  21Vianet Group (VNET) CEO Alvin Wang on Q1 2019 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -49.09% and price-to-book is 7.90.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here